Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
86 hedge funds and large institutions have $197M invested in Insys Therapeutics, Inc. in 2013 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 15 closing their positions.
100% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 15
33% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 21
31% more capital invested
Capital invested by funds: $151M → $197M (+$46.4M)
21% more funds holding
Funds holding: 71 → 86 (+15)
18% more call options, than puts
Call options by funds: $925K | Put options by funds: $782K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$12.1M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$10M |
| 3 |
TCM
Tamarack Capital Management
Carlsbad,
California
|
+$9.78M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$9.41M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$5.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$9.52M |
| 2 |
JP Morgan Chase
New York
|
-$5.65M |
| 3 |
Renaissance Technologies
New York
|
-$5.52M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$4.35M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$3.43M |
INSY Hedge Fund Activity: Q4 2013 in Review
86 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q4 2013, worth a combined $197M — up 31% from $151M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new INSY positions and 15 closed out — a net gain of 15 holders — while 28 added to existing stakes and 21 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $12.1M. The largest seller was Emerald Advisers, cutting an estimated $9.52M.
- 86 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q4 2013, up from 71 in Q3 2013.
- Funds reported $197M of Insys Therapeutics, Inc. stock for Q4 2013, up 31% quarter-over-quarter.
- 30 funds opened new Insys Therapeutics, Inc. positions in Q4 2013 and 15 closed out, a net change of +15 holders.
- The largest Insys Therapeutics, Inc. buyer in Q4 2013 was Consonance Capital Management, an estimated $12.1M added.
- The largest Insys Therapeutics, Inc. seller in Q4 2013 was Emerald Advisers, an estimated $9.52M sold.
Based on aggregated 13F filings for Q4 2013.